PeptideScanner
Unapproved↗Unapproved and safety records↗↗↗

BPC-157↗

Related names in cited records: Body protection compound 157↗

A research peptide represented by FDA compounding-review material and one selected trial-registry record.↗↗↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 29, 2026

We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications. 14

This version supersedes public version 1.

Evidence summary

What the cited records say

FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.↗↗↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

  • U.S. Food and Drug Administration↗↗
  • Hudson Biotech↗

Trial records

Dated source history

Updates connected to this profile

  1. Regulatory

    FDA committee met on seven peptide-related groups of bulk drug substances↗

    FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗

  2. Clinical trials

    BPC-157 hamstring study appears in trial registry↗

    ClinicalTrials.gov lists a recruiting BPC-157 study sponsored by Hudson Biotech.↗

Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance